

KFIN/CERT13(3)/SEP/2024

Date : October 7, 2024

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Worli, Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended September 30, 2024.

Dear Sir,


With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended September 30, 2024.

Description of Complaint	Opening Balance as on 01.07.2024	Received during the Period 01.07.2024 to 30.09.2024	Attended/Resolved during the Period 01.07.2024 to 30.09.2024	Pending as on 30.09.2024
Non-receipt of Dividend	NIL	06	06	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of shares	NIL	01	01	NIL
SEBI	NIL	07	06	01
Stock Exchange	NIL	NIL	NIL	NIL
ODR	NIL	02	02	NIL
Total	NIL	16	15	01

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Limited



Rajitha Cholleti
Vice President